Search results for "Milia"

showing 10 items of 1060 documents

Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE st…

2021

Background: Progressive familial intrahepatic cholestasis (PFIC) is an ultra-rare disease with a considerable burden on pediatric patients and their caregivers, impacting quality of life (QoL). The mortality rates highlight a significant need for efficacious treatments. Real-world data on associated costs and QoL are needed to gauge the potential impact of new pharmacological treatments. Methods: Clinical and socio-economic burden of PFIC on patients/caregivers, health systems, and society will be assessed. Patient/caregiver- and physician-level retrospective cross-sectional data will be collected from the US, UK, France, and Germany, for PFIC types 1, 2, 3. A representative sample of physi…

medicine.medical_specialtyATP Binding Cassette Transporter Subfamily BCaregiver BurdenDiseaseCholestasis Intrahepatic03 medical and health sciences0302 clinical medicineQuality of lifeCost of IllnessSurveys and QuestionnairesMedicineHumansPharmacology (medical)030212 general & internal medicineCase report formDisease burdenHealth policyRetrospective Studiesbusiness.industry030503 health policy & servicesHealth PolicyMortality rateProgressive familial intrahepatic cholestasisHealth technologyGeneral Medicinemedicine.diseaseCross-Sectional StudiesSocioeconomic FactorsFamily medicineQuality of Life0305 other medical sciencebusinessDelivery of Health Care
researchProduct

Chronic spontaneous urticaria or autoinflammatory disease? The therapeutic effect of omalizumab in a pediatric patient.

2018

Chronic spontaneous urticaria (CSU) is a clinical condition characterized by spontaneous or inducible recurrent wheals. This condition may significantly affect quality of life of patients and of their families. Etiology is not identified in 25-85% of cases that are indicated as 'idiopathic', because all diagnostic tests are negative. Autoimmune processes may be present in 30-50% of patients, although a definite etiological diagnosis is seldom possible. Some patients, in fact, have autoantibodies against the high-affinity IgE receptor FceR1 or IgE. These patients show an increased incidence of anti-thyroid autoantibodies and represent 30-50% of the patients designated as having CSU. Familial…

medicine.medical_specialtyAbdominal painAllergyDermatologyOmalizumabOmalizumabCold urticariaImmunoglobulin E03 medical and health sciences0302 clinical medicineFamilial Cold Autoinflammatory Syndromeautoinflammatory diseasemedicine030212 general & internal medicine030203 arthritis & rheumatologybiologybusiness.industrymedicine.diseaseDermatologyRashchronic idiopathic urticariabiology.proteinEtiologymedicine.symptombusinessmedicine.drugThe Journal of dermatological treatment
researchProduct

Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children.

2018

Dyslipdiemia can manifest at a young age, and it is a risk factor for atherosclerotic cardiovascular disease (ASCVD), the principal cause of mortality in developed nations. Therefore, treating it a...

medicine.medical_specialtyAdolescentFamilial hypercholesterolemiastatins03 medical and health sciences0302 clinical medicineEzetimibechildrenmedicinePharmacology (medical)Risk factorIntensive care medicinePharmacologyfamilial hypercholesterolemiaAtherosclerotic cardiovascular diseasebusiness.industryfungidyslipidemiafood and beveragesGeneral Medicinemedicine.diseaseYoung age030220 oncology & carcinogenesisbusinessDeveloped country030217 neurology & neurosurgeryDyslipidemiamedicine.drugezetimibeExpert opinion on pharmacotherapy
researchProduct

C4BQO in familial clustering of liver cirrhosis

1993

medicine.medical_specialtyCirrhosisbusiness.industryInternal medicineImmunologymedicineFamilial clusteringmedicine.diseasebusinessMolecular BiologyGastroenterologyMolecular Immunology
researchProduct

Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

2019

Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedPlacebolaw.inventionPCSK903 medical and health sciencesAge0302 clinical medicineRandomized controlled trialEzetimibeRisk FactorslawInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineAdverse effectAgedAlirocumabNutrition and Dieteticsbusiness.industryPCSK9SmokingAge FactorsCholesterol LDLMiddle Agedmedicine.diseaseCholesterolTreatment OutcomeConcomitantHypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Clinical Lipidology
researchProduct

Oxidative Stress and Chronic Inflammatory State Present in Familial Hypercholesterolemia is Reduced After a Fat Overload Rich in Unsaturated Fatty Ac…

2010

medicine.medical_specialtyEndocrinologyBiochemistryChemistryInternal medicineInternal MedicinemedicineGeneral MedicineFamilial hypercholesterolemiaCardiology and Cardiovascular Medicinemedicine.diseasemedicine.disease_causeOxidative stressAtherosclerosis Supplements
researchProduct

Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la…

2015

Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening disease characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) has recently published a clinical guide to diagnose and manage HoFH (Eur Heart J. 2014;35:2146-57). Both the Spanish Society of Atherosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF) consider this European Consensus document of great value and utility. However, there are particularities in our country which advise to ha…

medicine.medical_specialtyEzetimibeHomozygous familial hypercholesterolaemiaDiagnosisMedicinePharmacology (medical)Lipoprotein cholesterolNational healthEzetimibabusiness.industryAtherosclerotic cardiovascular diseaseDiagnósticoAféresisStatinsHipercolesterolemia familiar homocigotaLomitapidaEzetimibeLomitapidePatient managementLDL apheresisFamily medicineEuropean atherosclerosis societylipids (amino acids peptides and proteins)ApheresisCardiology and Cardiovascular MedicinebusinessEstatinasmedicine.drug
researchProduct

Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review

2020

Background: Dyslipidemia is the main factor involved in the occurrence and progression of coronary artery disease. Objective: The research strategy is aimed at analyzing new data on the pathophysiology of dyslipidemia involvement in coronary artery disease, the modalities of atherogenic risk estimation and therapeutic advances. Method: Scientific articles published in PubMed from January 2017 to February 2018 were searched using the terms "dyslipidemia" and "ischemic heart disease". Results: PCSK9 contributes to the increase in serum levels of low-density lipoprotein-cholesterol and lipoprotein (a). The inflammation is involved in the progression of hyperlipidemia and atherosclerosis. Hype…

medicine.medical_specialtyFamilial hypercholesterolemiaDiseaseCoronary Artery Disease030204 cardiovascular system & hematologyArticlestatinsCoronary artery disease03 medical and health sciences0302 clinical medicineproprotein convertase subtilisin/kexin type 9Risk FactorsInternal medicineHyperlipidemiamedicineHumans030212 general & internal medicinetriglyceridesCoronary atherosclerosisDyslipidemiasbusiness.industryPCSK9dyslipidemiaGeneral Medicinemedicine.diseaseCholesterolCardiologyArterial stiffnessCardiology and Cardiovascular MedicinebusinessDyslipidemiaCurrent Cardiology Reviews
researchProduct

Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020

2020

The recommendations of the semFYC's Program for Preventive Activities and Health Promotion (PAPPS) for the prevention of cardiovascular diseases (CVD) are presented. The following sections are included: Epidemiological review, where the current morbidity and mortality of CVD in Spain and its evolution as well as the main risk factors are described; Cardiovascular (CV) risk tables and recommendations for the calculation of CV risk; Main risk factors such as arterial hypertension, dyslipidemia and diabetes mellitus, describing the method for their diagnosis, therapeutic objectives and recommendations for lifestyle measures and pharmacological treatment; Indications for antiplatelet therapy, a…

medicine.medical_specialtyFamily medicineMedicina:Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings]030204 cardiovascular system & hematologyPharmacological treatment:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings]03 medical and health sciences0302 clinical medicineDiabetes mellitusDiabetes mellitusEpidemiologymedicine030212 general & internal medicineIntensive care medicine:Diseases::Cardiovascular Diseases [Medical Subject Headings]lcsh:R5-920:Diseases::Endocrine System Diseases::Diabetes Mellitus [Medical Subject Headings]business.industryMedicina de familia:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Atrial fibrillationGeneral MedicineAtención primariamedicine.diseasePrimary careCardiovasculardiseasesHealth promotionCardiovascular diseases:Health Care::Health Care Facilities Manpower and Services::Health Promotion [Medical Subject Headings]Preventive activitiesEnfermedades cardiovasculareslcsh:Medicine (General)Family PracticebusinessDyslipidemia
researchProduct

How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks fo…

2020

Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementation of the knowledge of FH, comparing country-specific approaches and providing real-world data about identification, management and treatment of FH individuals in t…

medicine.medical_specialtyGenotypeFamilial hypercholesterolemiaPopulationFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineGenetic dyslipidaemiasFamilial hypercholesterolemia; Genetic dyslipidaemias; Pathology registersInternal MedicineHumansMedicineGenetic Predisposition to DiseaseRegistries030212 general & internal medicineeducationIntensive care medicineHypolipidemic Agentseducation.field_of_studybusiness.industryGenetic disorderDiagnostic algorithmsGeneral MedicinePathology registersmedicine.diseaseClinical PracticePhenotypeItalyCardiovascular DiseasesHeart Disease Risk FactorsDisease riskIdentification (biology)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAlgorithmsAtherosclerosis Supplements
researchProduct